- Home
- MRSN vs PULM Comparison
MRSN vs PULM Comparison
Compare MRSN & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- PULM
- Stock Information
- Founded
- MRSN 2001
- PULM 2003
- Country
- MRSN United States
- PULM United States
- Employees
- MRSN N/A
- PULM N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- PULM Health Care
- Exchange
- MRSN Nasdaq
- PULM Nasdaq
- Market Cap
- MRSN 36.4M
- PULM 30.9M
- IPO Year
- MRSN 2017
- PULM N/A
- Fundamental
- Price
- MRSN $0.35
- PULM $6.31
- Analyst Decision
- MRSN Buy
- PULM
- Analyst Count
- MRSN 3
- PULM 0
- Target Price
- MRSN $4.00
- PULM N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- PULM 19.7K
- Earning Date
- MRSN 05-08-2025
- PULM 05-09-2025
- Dividend Yield
- MRSN N/A
- PULM N/A
- EPS Growth
- MRSN N/A
- PULM N/A
- EPS
- MRSN N/A
- PULM N/A
- Revenue
- MRSN $40,497,000.00
- PULM $7,806,000.00
- Revenue This Year
- MRSN N/A
- PULM N/A
- Revenue Next Year
- MRSN N/A
- PULM $134.88
- P/E Ratio
- MRSN N/A
- PULM N/A
- Revenue Growth
- MRSN 9.88
- PULM 6.96
- 52 Week Low
- MRSN $0.26
- PULM $1.72
- 52 Week High
- MRSN $3.83
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- MRSN 44.90
- PULM 49.72
- Support Level
- MRSN $0.31
- PULM $5.31
- Resistance Level
- MRSN $0.40
- PULM $6.07
- Average True Range (ATR)
- MRSN 0.05
- PULM 0.50
- MACD
- MRSN 0.01
- PULM 0.03
- Stochastic Oscillator
- MRSN 68.09
- PULM 63.59
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.